- All sections
- C - Chemistry; metallurgy
- C07D - Heterocyclic compounds
- C07D 207/14 - Nitrogen atoms not forming part of a nitro radical
Patent holdings for IPC class C07D 207/14
Total number of patents in this class: 413
10-year publication summary
25
|
22
|
36
|
36
|
30
|
47
|
25
|
25
|
22
|
9
|
2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
Principal owners for this class
Owner |
All patents
|
This class
|
---|---|---|
Takeda Pharmaceutical Company Limited | 2961 |
28 |
Bristol-myers Squibb Company | 5080 |
19 |
The Regents of the University of California | 18943 |
10 |
Taisho Pharmaceutical Co., Ltd. | 844 |
10 |
Mission Therapeutics Limited | 79 |
10 |
F. Hoffmann-La Roche AG | 7958 |
9 |
Oryzon Genomics S.A. | 103 |
9 |
ADT Pharmaceuticals, LLC | 14 |
9 |
Mitsubishi Tanabe Pharma Corporation | 579 |
8 |
H. Lundbeck A/S | 1252 |
8 |
Merck Sharp & Dohme LLC | 3689 |
7 |
Janssen Pharmaceutica N.V. | 3839 |
6 |
Dana-Farber Cancer Institute, Inc. | 2455 |
6 |
Theravance Biopharma R&D IP, LLC | 550 |
6 |
Incyte Holdings Corporation | 609 |
5 |
Novartis AG | 11238 |
4 |
Heptares Therapeutics Limited | 225 |
4 |
Kinki University | 225 |
4 |
Nektar Therapeutics | 503 |
4 |
Nippon Chemiphar Co., Ltd. | 233 |
4 |
Other owners | 243 |